Cell therapy in kidney transplantation: Focus on regulatory T cells

Nicholas A. Zwang, Joseph R. Leventhal*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


Renal transplantation is the renal replacement modality of choice for suitable candidates with advanced CKD or ESRD. Prevention of rejection, however, requires treatmentwith nonspecific pharmacologic immunosuppressants that carry both systemic and nephrologic toxicities. Use of a patient's own suppressive regulatory T cells (Tregs) is an attractive biologic approach to reduce this burden. Here, we review the immunologic underpinnings of Treg therapy and technical challenges to developing successful cell therapy. These issues include the selection of appropriate Treg subsets, ex vivo Treg expansion approaches, how many Tregs to administer and when, and how to care for patients after Treg administration.

Original languageEnglish (US)
Pages (from-to)1960-1972
Number of pages13
JournalJournal of the American Society of Nephrology
Issue number7
StatePublished - Jul 2017

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Cell therapy in kidney transplantation: Focus on regulatory T cells'. Together they form a unique fingerprint.

Cite this